Drugs / Human Milk Oligosaccharides
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06102213 | Sep 2023 → Aug 2024 | hematopoietic and lymphoid cell neoplasm | Prolacta Bioscience | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Milk Oligosaccharides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06102213 ↗ |
| Known as | HMO | “PBCLN-010: Human Milk Oligosaccharides (HMO).” NCT06102213 ↗ |
| Route | Oral | “HMO will be administered at 9.0 g orally twice a day (BID)” NCT06102213 ↗ |